Fermentozamestitel'naya terapiya u detey s mukopolisakharidozami v Rossii: osobennosti organizatsii, vnedrenie,perspektivy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article summarizes the experience of the introduction of enzyme replacement therapy (ERT) at the Research Center for Children’s Health RAMS; a model of organization of multi-stage comprehensive care for children with mucopolysaccharidosis (MPS) is presented.

Full Text

Restricted Access

References

  1. Козлова С.И., Демикова Н.С. Наследственные синдромы и медико-генетическое консультирование. М., 2007. С. 169-70.
  2. Коннет Л. Джонс. Наследственные синдромы по Дэвиду Смиту. М., 2011.
  3. Hopkin RJ, Grabowski GA. Lysosomal storage diseases. In: Fauci A, Kasper D, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill, 2005:2452-56.
  4. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, ed. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill, 2001:3421-52.
  5. Leighton SE, Papsin B, Vellodi A, Dinwiddie R, Lane R, et al. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2001;58:127-38.
  6. Peters C, Shapiro EG, Krivit W. Hurler syndrome: past, present, and future. J Pediatr 1998;133(1):7-9.
  7. Marucha J, Jurecka A, Syczewska M, et al. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatrica 2012; 101:183-8.
  8. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995;72(3):263-67.
  9. Valayannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010;5:5.
  10. Muenzer J, Beck M, Eng СM, et al. Multidisciplinary Management of Hunter Syndrome. Pediatrics December 2009;124:е1228-39.
  11. Muenzer J, Wraith J E, Clarke LA. International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: Management and Treatment Guidelines. Pediatrics January 2009;123:19-29.
  12. Thomas JA, Beck M, Clarke JT, et al. Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis 2010;33:421-27.
  13. Karageorgos L, Brooks D, Harmatz P, et al. Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy. Mol Genet Metab 2007;90;164-70.
  14. Wraith JE, Beck M, Lane R, et al. Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α-l-Iduronidase (Laronidase). Pediatrics 2007;120:e37-46.
  15. Burton BK, et al. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. European journal of pediatrics 2012;171(4): 631-39. (Epub. 2012 Mar 01).
  16. Giugliani R, Harmatz P, Wraith JE. Management Guidelines for Mucopolysaccharidosis VI. Pediatrics 2007;120(2):405-18.
  17. Holt JB, Poe MD, Escolar ML. Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II. Pediatrics 2011;127(5):e1258-65.
  18. Clarke LA, Wraith JE, Beck M, et al. Longterm Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I. Pediatrics 2009; 123:1 229-40.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies